Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator

Cataract Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00630019
• Other study ID #: VPH0107
• Status: Completed
• Phase: Phase 4
• First received: February 22, 2008
• Last updated: February 4, 2009
• Start date: February 2008

Study information

• Verified date: February 2009
• Source: Santen Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Compare ocular tissue levels following topical ocular instillation of 1.5% levofloxacin ophthalmic solution or an active comparator in subjects undergoing cataract surgery.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 96
• Est. primary completion date: October 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Capable of instilling eye drop

• Scheduled for cataract surgery with intraocular lens (IOL) implantation

• Be medically cleared for surgery

• Women must be postmenopausal (for at least 1 year), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control before entry, and must agree to continue to use the same method of contraception throughout the study

• Women of childbearing potential must have a negative urine pregnancy test at screening.

• Willing to adhere to the prohibitions and restrictions specified in this protocol.

• Subjects (or his/her legally acceptable representative) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.

Exclusion Criteria:

• Known allergy or other contraindication to the test article(s) or their components.

• Presence of any abnormality or significant illness in the eye that in the investigator's opinion could affect the subject's health or the study parameters.

• History of or presence of any corneal pathology or disease

• Presence of an active ocular infection (bacterial, viral or fungal), or positive history of ocular herpetic infection.

• History of severe dry eye syndrome.

• History or evidence of previous ocular surgery in the operative eye.

• History of any significant illness that could be expected to interfere with the study parameters.

• Use of disallowed therapies (systemic or topical):

• Fluoroquinolone anti-infective agents (systemic or topical) within 2 weeks of Visit 1 or anytime after Visit 1 for the duration of the study;

• Topical ophthalmic preparations (including tear substitutes and rewetting drops), within 1 week of Visit 1 or anytime after Visit 1 for the duration of the study (other than the study medication as restricted above), with the exception of non-steroidal topical ophthalmic drops

• Use of contact lenses in the 2 weeks prior to the study and for the duration of the study.

• Received an experimental drug or used an experimental medical device within 30 days before the planned start of treatment.

• Pregnant or breast-feeding.

• Any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study.

• Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.

Related Conditions & MeSH terms

• Cataract

Intervention

Drug:
• 1.5% levofloxacin ophthalmic solution
Topical application
• 0.5% moxifloxacin hydrochloride ophthalmic solution
Topical application

Locations

Country	Name	City	State
United States	Bucci Laser Vision & Ambulatory Surgery Center	Wilkes-Barre	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Santen Inc.	Vistakon Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concentration of levofloxacin and active control in the aqueous humor		Time of surgery
Secondary	Adverse Events		4 days